Article and Video CATEGORIES
Immunotherapy for Non-Squamous NSCLC: Should We be Using Biomarker Selection?
The immune checkpoint inhibitor Opdivo (nivolumab) shows better efficacy than Taxotere (docetaxel) for advanced non-squamous NSCLC, but this was seen only in patients with PD-L1 protein expression on their tumor. Should we be using this as a biomarker?
[powerpress]
Please feel free to offer comments and raise questions in our Discussion Forums.
Tags
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Article
The article describes the AVO treatment, a combination therapy for Chronic Lymphocytic Leukemia (CLL), particularly for high-risk patients. CLL is a slow-growing cancer where abnormal white blood cells accumulate. "High-risk" CLL refers to cases with specific genetic changes (e.g., in TP53) that make the disease harder to treat.
Image
Article
Da click aquí para más información y para registrarte ahora
Forum Discussions
Recent Comments
Hi Hopish hope, Welcome to…
By JanineT GRACE … on
colon cancer and HIV
By Hopish hope on